Cefiderocol
ApprovedRecruiting 1 views this week 0 watching⚡ Active
Interest: 50/100
50
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Drug Clearance After Severe Burn Injury
Conditions
Drug Clearance After Severe Burn Injury
Trial Timeline
Feb 16, 2026 → Feb 28, 2027
NCT ID
NCT07465432About Cefiderocol
Cefiderocol is a approved stage product being developed by Shionogi for Drug Clearance After Severe Burn Injury. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07465432. Target conditions include Drug Clearance After Severe Burn Injury.
What happened to similar drugs?
7 of 14 similar drugs in Drug Clearance After Severe Burn Injury were approved
Approved (7) Terminated (3) Active (5)
✅Polyene phosphatidylcholine injection 930 mg QD + Magnesium Isoglycyrrhizinate injection 200 mg QDHaisco Pharmaceutical GroupApproved
Hype Score Breakdown
Clinical
20
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03780140 | Pre-clinical | Completed |
| NCT07465432 | Approved | Recruiting |
| NCT05789199 | Pre-clinical | Completed |
| NCT05373615 | Phase 1 | Completed |
| NCT05314764 | Approved | Completed |
| NCT04995835 | Phase 1 | Completed |
| NCT03869437 | Phase 2 | Completed |
Competing Products
20 competing products in Drug Clearance After Severe Burn Injury